ascopubs.org25d
Long-term survival outcomes of atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma.
Efficacy and safety of HER2-targeted therapies in biliary tract cancer: A systematic review and meta-analysis of early phase clinical trials. 3-year, 4-year and 5-year OS rate of patients who receive ...
pharmaphorum7d
NICE backs first ophthalmic bevacizumab for NHS use
Outlook Therapeutics' Lytenava has become the first ophthalmic formulation of VEGF inhibitor bevacizumab to be cleared for use by the NHS in England and Wales for treating wet age-related macular ...